Minimally disseminated disease and outcome in overt orbital retinoblastoma

In this retrospective study of patients with overt orbital retinoblastoma, we evaluated minimally disseminated disease (MDD) in bone marrow and cerebrospinal fluid (CSF) using CRX and/or GD2 synthase as markers. Ten patients were evaluated—five (50%) at diagnosis and five upon relapse. MDD was detected in four cases (one in the bone marrow, two in the CSF, and in one case in both sites). All patients received chemotherapy and four received orbital radiotherapy. Seven patients relapsed or progressed and all of them died. Three patients remain in complete remission. There was no apparent correlation between MDD and the outcome.

[1]  G. Chantada,et al.  Combined high‐dose intra‐arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma , 2018, Pediatric blood & cancer.

[2]  S. Honavar,et al.  Orbital retinoblastoma: An update , 2017, Indian journal of ophthalmology.

[3]  T. Merchant,et al.  Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321). , 2017 .

[4]  D. Alonso,et al.  Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. , 2016, JAMA ophthalmology.

[5]  B. Chawla,et al.  Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. , 2016, Ophthalmology.

[6]  D. Abramson,et al.  Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery , 2016, PloS one.

[7]  D. Alonso,et al.  Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. , 2015, JAMA ophthalmology.

[8]  V. Segatori,et al.  Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours , 2015, Acta ophthalmologica.

[9]  D. Alonso,et al.  Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. , 2013, European journal of cancer.

[10]  S. Vishnubhatla,et al.  Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. , 2012, Ophthalmology.

[11]  M. Ali,et al.  Orbital retinoblastoma: Present status and future challenges - A review. , 2011, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

[12]  D. Alonso,et al.  Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. , 2010, Molecular medicine reports.

[13]  F. Berthold,et al.  Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. , 2009, Clinical chemistry.

[14]  C. Leal-Leal,et al.  Survival in extra-orbital metastatic retinoblastoma: treatment results , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[15]  C. Rodríguez-Galindo,et al.  A proposal for an international retinoblastoma staging system , 2006, Pediatric blood & cancer.

[16]  G. Chantada,et al.  Treatment of overt extraocular retinoblastoma. , 2003, Medical and pediatric oncology.